1472P_PR - Change of patient perceptions of chemotherapy side effects in breast and ovarian cancer patients

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Ovarian Cancer
Complications of Treatment
Bioethics, Legal, and Economic Issues
Breast Cancer
Presenter Beyhan Ataseven
Citation Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440
Authors B. Ataseven1, J. Frindte1, P. Harter1, G. Göke1, J. Holtschmidt2, C. Vogt1, A. Traut1, B. Vincenzo2, M. Vincent2, H. Florian1, S. Kuemmel2, S. Prader1, M. Sporkmann1, S. Schneider1, A. du Bois1
  • 1Gynecology And Gynecologic Oncology, Kliniken Essen Mitte Evang. Huyssens-Stiftung, 45136 - Essen/DE
  • 2Breast Unit, Kliniken Essen Mitte Evang. Huyssens-Stiftung, 45136 - Essen/DE



Previous studies demonstrated changes of patient perceptions (PP) and individual ranking of chemotherapy side effects (CSE) between 1983-2002. We updated this survey and evaluated changes in PP in comparison to previous studies and as longitudinal observation.


Patients with breast (BC) and ovarian cancer (OC) planned for chemotherapy were recruited in this prospective study. At three different visits (before (T1), week 12+/-3 (T2), and at the end of chemotherapy (T3)) patients were asked to identify out of 72 cards, displaying potential physical and non-physical CSE, the ten most burdensome and rank them finally to top five by severity.


In total, 141 patients (95 BC and 45 OC) were recruited. All three interviews were completed in 113 patients. The most severe CSE reported was “difficulty sleeping” compared to “vomiting” in 1983, “nausea” in 1993, and “affects my family/partner” in 2002 (Table 1a). “Loss of hair” remained a top concern over all studies. Over the complete observation period “affects my family/partner” and “difficulty sleeping” were among the top five severe side effects. “Feeling of not coping” and “nausea” were ranked only at T1, but not at T2/T3. “Loss of hair” was ranked at T1/T2, but no longer at T3. In contrast, “numbness in limbs” became relevant in T2/T3 (Table 1b).


Patient perceptions of CSE have changed markedly compared with previous studies. However, “loss of hair” has remained an unsolved problem over decades. Furthermore, we demonstrated that PP of CSE changes over the treatment period. However, social concerns like “affecting family/partner” remain long-lasting problems.

Clinical trial identification

Legal entity responsible for the study

Beyhan Ataseven




All authors have declared no conflicts of interest.Table:


Table 1a Ranking of side effects1983 (Coates et al.)1993 (Griffin et al.)2002 (Carelle et al.)2016 Current study
1VomitingNauseaAffects my family or partnerDifficulty sleeping
2NauseaConstantly tiredLoss of hairAffects my family or partner
3Loss of hairLoss of hairConstantly tiredLoss of hair
4Thought of coming treatmentThought of coming for treatmentAffects my work, home dutiesNumbness in limbs
5Length of time treatment takes at clinicVomitingAffects my social activitiesShortness of breath
Table 1b RankingT1 (before initiation of chemotderapy)T2 (after 12+/-3 w weeks of chemotderapy start)T3 (end of chemotderapy + /- 2 weeks)
1Affects my family or partnerDifficulty sleepingDifficulty sleeping
2Feeling of not coping with treatmentAffects my family or partnerAffects my family or partner
3Loss of hairNumbness in limbsNumbness in limbs
4NauseaLoss of hairAffects my work, home duties
5Difficulty sleepingShortness of breathPins and needles in limbs (fingers, toes)